CA3121830A1 - Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome - Google Patents

Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome Download PDF

Info

Publication number
CA3121830A1
CA3121830A1 CA3121830A CA3121830A CA3121830A1 CA 3121830 A1 CA3121830 A1 CA 3121830A1 CA 3121830 A CA3121830 A CA 3121830A CA 3121830 A CA3121830 A CA 3121830A CA 3121830 A1 CA3121830 A1 CA 3121830A1
Authority
CA
Canada
Prior art keywords
formulation
pentylphenyl
acetate
improving
histology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3121830A
Other languages
English (en)
French (fr)
Inventor
Lyne Gagnon
Pierre Laurin
Frank CESARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal R&D Biosciences Inc
Original Assignee
Liminal R&D Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal R&D Biosciences Inc filed Critical Liminal R&D Biosciences Inc
Publication of CA3121830A1 publication Critical patent/CA3121830A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3121830A 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome Pending CA3121830A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775849P 2018-12-05 2018-12-05
US62/775,849 2018-12-05
PCT/CA2019/051753 WO2020113340A1 (en) 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome

Publications (1)

Publication Number Publication Date
CA3121830A1 true CA3121830A1 (en) 2020-06-11

Family

ID=70973699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3121830A Pending CA3121830A1 (en) 2018-12-05 2019-12-05 Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome

Country Status (6)

Country Link
US (1) US20220016060A1 (https=)
EP (1) EP3890717A4 (https=)
JP (1) JP2022510436A (https=)
AU (1) AU2019393347A1 (https=)
CA (1) CA3121830A1 (https=)
WO (1) WO2020113340A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761061A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
EA022445B1 (ru) * 2009-05-04 2016-01-29 Прометик Байосайенсиз Инк. Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения
CN105997967B (zh) * 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物

Also Published As

Publication number Publication date
WO2020113340A1 (en) 2020-06-11
EP3890717A1 (en) 2021-10-13
US20220016060A1 (en) 2022-01-20
EP3890717A4 (en) 2022-08-24
JP2022510436A (ja) 2022-01-26
AU2019393347A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
JP5663699B2 (ja) ピラゾール誘導体及びその医薬用途
EP2680836B1 (en) New compositions for treating neurological disorders
US11325904B2 (en) Tropinol esters and related compounds to promote normal processing of APP
US20230414541A1 (en) Methods of treating neurodegenerative disorders in a particular population
CN121695155A (zh) 减少与甲状腺相关的副作用的方法
EP2128171A1 (en) Agent for prevention or treatment of iron overload
US11685713B2 (en) Small molecule SHC blockers used for treating liver disease and metabolic disease
US20190134000A1 (en) Compounds to promote normal processing of app
US8846755B2 (en) Sulfonamides for the prevention of diabetes
US20220280451A1 (en) Treatment of copper disorder
CA3121830A1 (en) Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome
JP6454436B1 (ja) ペマフィブラートを含有する医薬
US20180250249A1 (en) Methods of treating neurodegenerative disorders in a particular population
CN109498623A (zh) 改善肝功能的方法
CN120284970A (zh) Cb-839在制备治疗糖尿病肾脏病药物中的应用
WO2024249509A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
US9517217B2 (en) Immune cell activation inhibitor and use thereof
JP2011519877A (ja) インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物
JP2004339068A (ja) 半月体形成性腎炎の予防又は治療剤
JP2008303144A (ja) アミロイド疾患の治療およびモニタリングのための薬剤
JP2007106710A (ja) 糖尿病性腎症の予防及び／又は治療剤
HK1190607B (en) New compositions for treating neurological disorders
HK1190607A (en) New compositions for treating neurological disorders
WO2010104176A1 (ja) メガリンタンパク切断阻害剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211216